VarCov Co’s Viking Therapeutics VKTX Stock Holding History

VarCov Co’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$543K	Sell	13,926 -2,114	-13%	-$68.3K	0.21%	172
2026 Q1	$522K	Buy	+16,040	New	+$516K	0.19%	199

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

VarCov Co's VKTX Position: Q2 2026 in Review

VarCov Co reduced its Viking Therapeutics (VKTX) stake by 13% in Q2 2026, selling an estimated $68.3K and leaving 13,926 shares worth $543K. The position accounts for 0.21% of the portfolio, ranked #172.

VarCov Co first reported a position in VKTX in Q1 2026 and has held it in 2 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

VarCov Co held 13,926 shares of Viking Therapeutics worth $543K as of Q2 2026.
VarCov Co sold 2,114 Viking Therapeutics shares in Q2 2026, an estimated $68.3K.
Viking Therapeutics made up 0.21% of VarCov Co's portfolio in Q2 2026, its #172 holding.
VarCov Co first reported a position in Viking Therapeutics in Q1 2026 and has held it in 2 quarters since.
432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on VarCov Co's 13F filing for Q2 2026, filed 14 Aug 2026.